
Ioanna Giopanou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9285250/publications.pdf Version: 2024-02-01



IOANNA CIOPANOLI

#	Article	IF	CITATIONS
1	Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight. Cells, 2019, 8, 815.	1.8	109
2	Mast cells mediate malignant pleural effusion formation. Journal of Clinical Investigation, 2015, 125, 2317-2334.	3.9	89
3	Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma. Nature Communications, 2019, 10, 1405.	5.8	68
4	Club cells form lung adenocarcinomas and maintain the alveoli of adult mice. ELife, 2019, 8, .	2.8	46
5	Ontogenetic differentiation of swimming performance in Gilthead seabream (Sparus aurata, Linnaeus) Tj ETQq1	1 0,78431 0.7	4 rggBT /Ove
6	Deficiency in apolipoprotein E has a protective effect on dietâ€induced nonalcoholic fatty liver disease in mice. FEBS Journal, 2011, 278, 3119-3129.	2.2	39
7	lκB Kinase α Is Required for Development and Progression of <i>KRAS</i> -Mutant Lung Adenocarcinoma. Cancer Research, 2018, 78, 2939-2951.	0.4	36
8	Beneficial Impact of CCL2 and CCL12 Neutralization on Experimental Malignant Pleural Effusion. PLoS ONE, 2013, 8, e71207.	1.1	33
9	<i> <scp>NRAS</scp> </i> destines tumor cells to the lungs. EMBO Molecular Medicine, 2017, 9, 672-686.	3.3	31
10	Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis. Oncolmmunology, 2017, 6, e1256528.	2.1	29
11	Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-Ĩ²Ĩ' addiction in malignant pleural effusion. Nature Communications, 2018, 9, 672.	5.8	28
12	Comprehensive Evaluation of Nuclear Factor-l̂ [®] l' Expression Patterns in Non-Small Cell Lung Cancer. PLoS ONE, 2015, 10, e0132527.	1.1	25
13	Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study. BioMed Research International, 2014, 2014, 1-8.	0.9	16
14	Interleukin-1β provided by KIT-competent mast cells is required for <i>KRAS</i> -mutant lung adenocarcinoma. Oncolmmunology, 2019, 8, e1593802.	2.1	15
15	Tobacco chemical-induced mouse lung adenocarcinoma cell lines pin the prolactin orthologue proliferin as a lung tumour promoter. Carcinogenesis, 2019, 40, 1352-1362.	1.3	14
16	Osteopontin drives KRAS-mutant lung adenocarcinoma. Carcinogenesis, 2020, 41, 1134-1144.	1.3	14
17	Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors. Cancer Medicine, 2019, 8, 1486-1499.	1.3	13
18	RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies. Critical Reviews in Oncology/Hematology, 2020, 146, 102859.	2.0	12

IOANNA GIOPANOU

#	Article	IF	CITATIONS
19	KRAS signaling in malignant pleural mesothelioma. EMBO Molecular Medicine, 2022, 14, e13631.	3.3	12
20	The expression of p-mTOR and COUP-TFII correlates with increased lymphangiogenesis and lymph node metastasis in prostate adenocarcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 311.e27-311.e35.	0.8	11
21	Synergistic Combination of Calcium and Citrate in Mesoporous Nanoparticles Targets Pleural Tumors. CheM, 2021, 7, 480-494.	5.8	11
22	Lung carcinogenesis and fibrosis taken together. Current Opinion in Pulmonary Medicine, 2017, 23, 290-297.	1.2	5
23	A link between <i>Rel</i> B expression and tumor progression in laryngeal cancer. Oncotarget, 2017, 8, 114019-114030.	0.8	4
24	An airway epithelial origin for tobacco carcinogen-induced lung adenocarcinoma. , 2015, , .		1